Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females

Status Completed

Clinical Trial Summary

Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet and reducing dietary fat absorption by up to 30%. The effect of this drug on human blood fatty acid profile has not been described yet. The FA composition of RBCs, plasma and platelets can be used to monitor of many pathological processes. This study presents alteration of FA composition in RBCM and phospholipids, triglycerides and cholesteryl esters from plasma of health obese female volunteers treated with nutritional orientation and orlistat (120 mg t.i.d) for 3 months.

Clinical Trial Description

Obesity treatment requires lifestyle changes such as diet, exercise, and behavioral therapy. Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet, from binding to the lipase enzyme active sites thus halting their subsequent breakdown into monoglycerides and free fatty acids necessary for fat digestion, reducing dietary fat absorption by up to 30%. The effect of this drug on human blood fatty acid profile has not been described yet.

The FA profile is typical of each lipid and tissue, however, alterations in diets, pathological processes, drugs intervention, cigarettes and alcohol consumption can alter the FA profile. The FA composition of RBCs, plasma and platelets can be used to monitor these processes. This study presents alteration of FA composition in RBCM and phospholipids, triglycerides and cholesteryl esters from plasma of health obese female volunteers treated with nutritional orientation and orlistat (120 mg t.i.d) for 3 months. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Overweight

Clinical Trial Details

NCT number	NCT01414465
Study type	Interventional
Source	University of Campinas, Brazil
Contact
Status	Completed
Phase	N/A
Start date	October 2009
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04507867` - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III	N/A
Terminated	`NCT03299881` - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss	N/A
Completed	`NCT02805478` - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting	`NCT02558920` - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed	`NCT03759743` - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject	N/A
Completed	`NCT03610958` - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.	N/A
Completed	`NCT03678766` - CHARGE: Controlling Hunger and ReGulating Eating	N/A
Completed	`NCT04430465` - Effects of Wholegrains on Children's Health (KORN)	N/A
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT05376865` - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers	N/A
Completed	`NCT03625427` - Effect of Palmitoleic Acid on C-reactive Protein	N/A
Active, not recruiting	`NCT03435445` - Online Platform for Healthy Weight Loss (POEmaS)	N/A
Enrolling by invitation	`NCT05576116` - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics	N/A
Recruiting	`NCT05249465` - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention	N/A
Active, not recruiting	`NCT06023095` - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities	Phase 1
Completed	`NCT03648892` - Brain Dopamine Function in Human Obesity	Early Phase 1
Not yet recruiting	`NCT05751993` - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions	N/A
Recruiting	`NCT02887950` - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause	N/A
Terminated	`NCT02743598` - Liraglutide for HIV-associated Neurocognitive Disorder	Phase 4
Completed	`NCT02829229` - Community-based Obesity Treatment in African American Women After Childbirth	N/A